Associations Among Androgens, Estrogens, and Natriuretic Peptides in Young Women Observations From the Dallas Heart Study by Chang, Alice Y. et al.
T
t
(
i
g
n
F
D
D
b
D
R
d
s
I
M
s
2
Journal of the American College of Cardiology Vol. 49, No. 1, 2007
© 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00
PAssociations Among Androgens,
Estrogens, and Natriuretic Peptides in Young Women
Observations From the Dallas Heart Study
Alice Y. Chang, MD, Shuaib M. Abdullah, MD, Tulika Jain, MD, Harold G. Stanek, MS,
Sandeep R. Das, MD, MPH, Darren K. McGuire, MD, MHSC, Richard J. Auchus, MD, PHD,
James A. de Lemos, MD
Dallas, Texas
Objectives We sought to determine if natriuretic peptides are associated with estrogen and androgen status in a population
study of young women without known cardiac disease.
Background Circulating concentrations of plasma B-type natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP) are
higher in women than in men, and they may be influenced by estrogens and androgens.
Methods Cardiac magnetic resonance imaging, dual energy X-ray absorbtiometry, and measurements of BNP, NT-proBNP,
follicle-stimulating hormone (FSH), total testosterone, and sex hormone-binding globulin (SHBG), were performed
in 682 women (ages 35 to 49 years) participating in the Dallas Heart Study.
Results In multivariable analyses adjusting for age, race/ethnicity, body mass index (BMI), serum creatinine, left ventric-
ular mass and left ventricular ejection fraction 55%, menopausal status, and FSH were not associated with
BNP and NT-proBNP. In contrast, higher SHBG was associated with higher BNP and NT-proBNP, while the free
androgen index and calculated free testosterone were inversely associated with BNP and NT-proBNP (p 
0.0001 for each). Addition of SHBG or any measure of free testosterone to the multivariable models modified
the effect of BMI and lean mass, such that measures of body composition were no longer significantly associ-
ated with BNP or NT-proBNP.
Conclusions Among young women, measures of free testosterone were independently and inversely associated with BNP and
NT-proBNP. These results suggest that circulating free testosterone, not estradiol, mediates gender differences
in natriuretic peptides. In addition, the association between higher BMI and lean body mass with natriuretic pep-
tides may be mediated by testosterone. (J Am Coll Cardiol 2007;49:109–16) © 2007 by the American College
of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.10.040t
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mhree recent population-based studies have demonstrated
hat circulating concentrations of B-type natriuretic peptide
BNP) and N-terminal proBNP (NT-proBNP) are higher
n women than in men (1–3). The biologic basis for this
ender difference in natriuretic peptide concentrations has
ot been delineated. Understanding the factors contributing
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006, accepted October 18, 2006.o gender differences in BNP and NT-proBNP may im-
rove the discriminatory value of these measurements for
creening and diagnostic purposes. The identification of
echanisms responsible for these gender differences also
ay provide novel insights into gender differences in car-
iovascular physiology and pathophysiology that would have
mplications for the treatment and prevention of heart
isease.
Previous studies have suggested an association between
xogenous estrogen and circulating natriuretic peptide con-
entrations in post-menopausal women. A population-
ased study from Olmsted County, Minnesota, found
odestly higher BNP concentrations in older women who
ere treated with oral estrogens versus those who were not
reated (3). However, this study did not obtain other
easures of hormone status aside from self-report of meno-ause. A subsequent experimental study in post-menopausal
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Androgens, Estrogens, and Natriuretic Peptides January 2/9, 2007:109–16women demonstrated a 3-fold
increase in mean BNP concen-
trations after 3 months of trans-
dermal estradiol administration (4).
Observed BNP changes after
puberty also suggest that gonadal
steroid hormones mediate gen-
der differences in natriuretic pep-
tides. Mean BNP concentrations
did not differ in 43 boys and girls
younger than 10 years of age but
were significantly higher in girls
(12.1 pg/ml) compared with boys
(5.1 pg/ml, p  0.001) 10 years
or older (5). No study to date has
examined the influence of en-
dogenous estrogens and andro-
gens on circulating natriuretic
peptide concentrations in pre-
menopausal women, the group
for whom the greatest variation
would be expected.
We tested the hypothesis that
lasma BNP and NT-proBNP would be associated with
strogen status in a population study of young adult women
ithout known cardiac disease, using various measurements
f reproductive hormone status: menopausal status, oral
strogen use, follicle-stimulating hormone (FSH), sex
ormone-binding globulin (SHBG), total testosterone
TT), free androgen index (FAI), and calculated free tes-
osterone (cFT). Because there is an established influence of
onadal steroids on body composition, we also evaluated
hether estrogen and free testosterone status modified the
reviously demonstrated associations between body compo-
ition and natriuretic peptides in this population (6–9).
ethods
tudy population. The Reynolds Women’s Study is a
ubstudy of the Dallas Heart Study, a probability-based
ample of Dallas County adults, oversampled for African
mericans (n  6,101). Details of the Dallas Heart Study
esign and characteristics of the enrolled cohort have been
reviously described (10). The study protocol was approved
y the University of Texas Southwestern Medical Center
nstitutional Review Board, and all participants provided
ritten informed consent to participate in the study.
ubjects and data collection. The Reynolds Women’s
tudy obtained additional reproductive health and men-
trual cycle information by survey, hormonal measurements,
nd pelvic imaging in women, ages 35 to 49 years, to
xamine the relationship of the subclinical and clinical
olycystic ovarian syndrome phenotypes to preclinical and
linical heart disease. The Reynolds Women’s Study was
erformed in 3 visits. Of the 1,179 women between the ages
Abbreviations
and Acronyms
BMI  body mass index
BNP  B-type natriuretic
peptide
cFT  calculated free
testosterone
DEXA  dual energy X-ray
absorbtiometry
FAI  free androgen index
FSH  follicle-stimulating
hormone
LVH  left ventricular
hypertrophy
MRI  magnetic resonance
imaging
NT-proBNP  N-terminal
pro-B-type natriuretic
peptide
SHBG  sex hormone-
binding globulin
TT  total testosteronef 35 and 49 years completing the visit 1 survey, 937eturned for visit 2 to provide blood and urine samples. At
isit 3, 827 women were age-eligible for an additional
eproductive health survey and pelvic magnetic resonance
maging (MRI) to assess ovarian size and structure. In
ddition, as part of the overall study design, cardiac MRI
nd total body dual energy X-ray absorbtiometry (DEXA)
maging were performed at visit 3. For the purposes of this
nalysis, we included only those women who had complete
ormonal profiles (FSH, SHBG, and TT) and albumin,
NP, and NT-proBNP measurements from visit 2, as well
s DEXA and cardiac MRI results from visit 3. We
xcluded subjects with a self-reported history of heart failure
n  20), which also included one woman with a creatinine
2 mg/dl, leaving a final study population of 682 women
Fig. 1). The baseline characteristics of this study popula-
ion (n 682) were similar to the 497 women ages 35 to 49
ears (n  497) who were not included, except for a
ignificantly lower percentage of African Americans in the
tudy group (data not shown). However, the racial compo-
ition of the study population (49% African American)
pproximates the parent study racial composition (50%
frican American) (10).
Figure 1 Overview of Reynolds Women’s Study
and Subject Selection for Current Analysis
BMI  body mass index; DEXA  dual energy X-ray absorbtiometry; DHS  Dal-
las Heart Study; MRI  magnetic resonance imaging.
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January 2/9, 2007:109–16 Androgens, Estrogens, and Natriuretic Peptidesssays. Venous blood was collected in standard blood
ollection tubes containing ethylene diamine tetraacetic acid
or plasma and in serum separator tubes for serum. Samples
ere maintained at 4°C for 4 h and then centrifuged
1,430 g for 15 min) at 4°C. Plasma or serum supernatant
as separated and frozen at 70°C until assayed. B-type
atriuretic peptide was measured on a TECAN Genesis
SP 200/8 robotic high-throughput platform (Biosite Inc.,
an Diego, California) (11), and NT-proBNP was mea-
ured on the Elecsys proBNP platform (Roche Diagnostics,
ndianapolis, Indiana) (12). The coefficient of variation for
he BNP assay averaged 11% at a concentration of 30 ng/l
nd 6% at concentrations 60 ng/l; the coefficient of
ariation for the NT-proBNP assay was 3% at a concentra-
ion of 280 ng/l and 3% at a concentration of 6,000 ng/l.
Measurements of FSH, LH, and SHBG were performed
n serum samples using 2-site immunoradiometric sand-
ich assays from Diagnostic Systems Laboratories (Web-
ter, Texas). For FSH, the lower detection limit was 0.1
U/l, and the coefficient of variation was 3.6% at a concen-
ration of 6.7 IU/l, and 3.1% at 54 IU/l. For the SHBG
ssay, the lower limit of detection was 3 nmol/l with a
oefficient of variation of 3.7% at a concentration of 92
mol/l. Albumin was measured by spectrophotometry.
Measurement of TT was performed on plasma samples
ith a competitive radioimmunoassay from Diagnostic
ystems Laboratories (DSL-4100). The lower limit for
Figure 2 Algorithm for Determining Menopausal Status in the D
See text for details. The group distributions are pre-menopausal women, n  939
salpingo-oophorectomy; FSH  follicle-stimulating hormone; LMP  last menstrualetection was 0.05 ng/ml with a coefficient of variation of
.7% at a concentration of 0.52 ng/ml. The formula
T/SHBG  100 was used to calculate FAI. The cFT was
alculated from measured values of albumin, TT and
HBG using equations derived from the laws of mass action
s reported by Vermeulen et al. (13). Both derived variables
f cFT and FAI have been validated as estimates of
nbound circulating testosterone in women (13,14).
maging. Cardiac MRI was performed for the assessment
f cardiac structure and function as previously described in
etail (15–17). Using DEXA data, we divided body com-
osition into 3 components: lean mass, fat mass, and bone
ass, as previously described (18). Scans were obtained
rom a bone densitometer in array mode (Delphi W,
ologic, Bedford, Massachusetts) and analyzed with Oasis
oftware (Hologic) to quantify body composition.
enopausal variables. Menopausal status was defined by
combination of survey variables, FSH, and adjudication by
elvic MRI when necessary (Fig. 2). Oral estrogen use was
scertained by questionnaire as use of oral contraceptives or
ormone-replacement therapy.
tatistical analyses. Statistical analyses were performed
sing SAS software (Version 9.1, SAS Corporation, Cary,
orth Carolina). In univariable analyses, Spearman corre-
ation coefficients were used to assess the association be-
ween natriuretic peptides and gonadal steroid hormones
nd SHBG. Because of their non-normal distributions,
Heart Study
menopausal, n  692; and unclear hormonal status, n  340. BSO  bilateral
; PCOS  polycystic ovarian syndrome.allas
; post-
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Androgens, Estrogens, and Natriuretic Peptides January 2/9, 2007:109–16T-proBNP, BNP, FSH, SHBG, and TT were log-
ransformed when performing multivariable analysis. Mul-
iple linear regression analysis was performed with log BNP
r log NT-proBNP as the dependent variables and the
ndependent variables of post-menopausal status, FSH,
ody mass index (BMI), creatinine, age, race, left ventricular
LV) mass, reduced LV ejection fraction (55%) and oral
strogen use to develop the baseline model. Subsequent
odels added log SHBG, log TT, log FAI, and log cFT
ndividually to the baseline model. For the last analysis,
tandardized estimates to compare the relative effect size of
he variables in the predictive model were calculated by
tandardizing all variables to a mean of 0 and a variance of 1.
he Cochran-Armitage trend test was used to compare
NP and NT-proBNP across increasing quartiles of
HBG, TT, and cFT, whereas the Scheffe post hoc test was
sed to analyze pair-wise comparisons.
esults
he study population comprised 682 women. Baseline
haracteristics stratified by NT-proBNP above versus below
he median value of 37.2 ng/l are shown in Table 1. Women
ith NT-proBNP concentrations above the median value
ere older, more often white, had a lower BMI, and were
ore likely to have left ventricular hypertrophy (LVH). No
ifferences in BNP or NT-proBNP concentrations were
bserved between pre- and post-menopausal women despite
ignificant differences in age and oral estrogen use. Among
ost-menopausal women, BNP or NT-proBNP concentra-
ions were similar among oral estrogen users and nonusers
for BNP: median 5.4 interquartile range [0, 15.5] vs.
edian 2.7 interquartile range [0, 11.4], p  0.24; for
T-proBNP: median 38.8 interquartile range [22.0, 79.0]
Baseline Characteristics for Study PopulationStratified By NT-proBNP Median, 37.2 ng/l*†
Table 1 Baseline Characteristics for StudyStratified By NT-proBNP Median, 3
Age, yrs‡
African American§
Prior myocardial infarction
Hypertension
Diabetes mellitus
Oral estrogen use
Post-menopausal
Body mass index (kg/m2)§
Left ventricular hypertrophy‡
Left ventricular ejection fraction 55%
Serum creatinine (mg/dl)
Follicle-stimulating hormone (IU/l)
Sex hormone-binding globulin (nmol/l)
Calculated free testosterone (pmol/l)
*Women with a history of congestive heart failure or creatinine 2 mg
continuous variables, or percentage for categorical variables; ‡p 0.05s. median 38.4 interquartile range [18.4, 74.1], p  0.70). Bhus, we were unable to demonstrate an association be-
ween BNP or NT-proBNP and estrogens in this cohort.
nivariable associations between hormones and natri-
retic peptides. Spearman correlation coefficients between
ormone concentrations and natriuretic peptide concentra-
ions are presented in Table 2. Both BNP and NT-proBNP
ere positively correlated with SHBG and inversely corre-
ated with TT, FAI, and cFT. In contrast, no significant
orrelations were observed between FSH and LH and either
atriuretic peptide measurement. Concentrations of BNP
nd NT-proBNP increased significantly across quartiles of
HBG and decreased significantly across quartiles of cFT
Fig. 3). These data suggest that androgens are inversely
ssociated with BNP and NT-proBNP.
ultivariable analysis evaluating natriuretic peptides
nd hormonal status. In multiple linear regression models
djusting for potential confounders, post-menopausal status
nd FSH were not associated with either log transformed
NP or NT-proBNP (Table 3, Model 1). In contrast,
igher levels of SHBG were independently associated with
igher BNP and NT-proBNP concentrations (Model 2),
hereas higher TT, FAI, and cFT were independently
ulation
ng/l*†
elow Median
(n  341)
Above Median
(n  341)
.0 (38.0, 45.0) 42.0 (38.0, 46.0)
57.8 40.5
0.3 0.3
26.3 27.7
8.2 7.3
11.4 10.9
15.8 17.6
.5 (26.4, 36.1) 29.5 (24.7, 34.9)
2.4 5.6
0.3 1.2
80 (0.70, 0.80) 0.70 (0.70, 0.80)
3.8 (2.4, 7.8) 4.1 (2.7, 8.5)
.0 (84.0, 188.0) 162.0 (106.0, 235.0)
.3 (9.2, 24.0) 10.9 (6.9, 18.1)
re excluded; †results presented as median (25th, 75th percentile) for
en groups; §p 0.006 between groups; p 0.0001 between groups.
pearman Correlation Coefficientsetween Hormones and Natriure ic Peptides
Table 2 Spearman Correlation CoefficientsBetween Hormones and Natriuretic Peptides
BNP NT-proBNP
Rho p Value Rho p Value
Follicle-stimulating hormone 0.037 0.34 0.033 0.39
Luteinizing hormone 0.029 0.44 0.017 0.65
Sex hormone-binding globulin 0.161 0.0001 0.253 0.0001
Total testosterone 0.113 0.003 0.088 0.02
Free androgen index 0.162 0.0001 0.243 0.0001
Calculated free testosterone 0.155 0.0001 0.233 0.0001Pop
7.2
B
41
30
0.
114
15NP  B-type natriuretic peptide; NT-proBNP  N-terminal pro-B-type natriuretic peptide.
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January 2/9, 2007:109–16 Androgens, Estrogens, and Natriuretic Peptidesssociated with lower BNP and NT-proBNP concentra-
ions (Table 3, Models 3 to 5).
The addition of log SHBG, log TT, log FAI, or log cFT
o the multivariable models modified the effect of BMI,
uch that BMI was no longer significantly associated with
NP or NT-proBNP (Table 4, Models 1 to 4). The
odifying effect of free testosterone and SHBG also was
een when lean body mass was substituted for BMI in the
odels (Table 4, Models 6 to 9). Moreover, comparing the
tandardized parameter estimates, measurements of free
Figure 3 Association Between Natriuretic Peptides, Calculated
Data points represent median (25th and 75th percentiles) for each quartile of eac
proBNP  N-terminal pro-B-type natriuretic peptide; SHBG  sex hormone-binding
Multivariable Associations Between MenopausaVariables, Hormones, and Natriuretic P ptides
Table 3 Multivariable Associations BetweenVariables, Hormones, and Natriureti
Log-Tra
Beta  SE
Model 1†
Post-menopausal 0.399 0.2
Log (follicle-stimulating hormone) 0.075 0.0
Model 2‡
Log (sex hormone-binding globulin) 0.403 0.1
Model 3‡
Log (total testosterone) 0.334 0.1
Model 4‡
Log (free androgen index) 0.320 0.0
Model 5‡
Log (calculated free testosterone) 0.329 0.0
*The beta coefficient  standard error (SE) describes the magnitude a
variable (log-transformed BNP or NT-proBNP); †models adjusted for a
mass, race, and oral estrogen use; ‡models adjusted for post-menopa
ejection fraction 55%, left ventricular mass, race, and oral estrogen use.
BMI  body mass index; BNP  B-type natriuretic peptide; NT-proBNP  Nestosterone status contributed more to the model than
MI or lean body mass (Table 4). In summary, these
nalyses confirm a strong influence of androgens on natri-
retic peptide concentrations in young women.
iscussion
n a population study of young adult women without known
ardiac disease, we did not demonstrate an association
etween estrogen status, as measured by post-menopausal
Testosterone, and Sex Hormone-Binding Globulin
ble. BNP  B-type natriuretic peptide; cFT  calculated free testosterone; NT-
n.
opausal
ptides
ed BNP Log-Transformed NT-proBNP
p Value Beta  SE* p Value
0.054 0.017 0.157 0.91
0.285 0.036 0.053 0.50
0.0001 0.483 0.077 0.0001
0.01 0.232 0.0995 0.02
0.0001 0.328 0.056 0.0001
0.0001 0.335 0.060 0.0001
ction of the association of the independent variable to the dependent
atinine, BMI, left ventricular ejection fraction 55%, left ventricular
g (follicle stimulating hormone), age, creatinine, BMI, left ventricularFree
h varia
globulil
Men
c Pe
nsform
*
07
71
04
31
75
80
nd dire
ge, cre
use, lo-terminal pro-B-type natriuretic peptide.
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Androgens, Estrogens, and Natriuretic Peptides January 2/9, 2007:109–16tatus, oral estrogen use or FSH concentrations, and plasma
NP and NT-proBNP concentrations. In contrast, we
bserved a positive association between SHBG and natri-
retic peptides and inverse associations between all mea-
ures of circulating free testosterone (FAI and cFT) and
atriuretic peptides even after adjusting for other factors
nown to influence natriuretic peptide concentrations, in-
luding structural and functional cardiac parameters, renal
unction, and BMI. In addition, we found that after
ccounting for the free testosterone status or SHBG, the
nfluence of body composition on natriuretic peptides was
arkedly attenuated.
re gender differences in natriuretic peptides mediated
y androgens rather than estrogens? Our findings do not
upport the notion that estrogens are primarily responsible
or gender differences in BNP, as has been previously
uggested (3,4). Rather, the present findings suggest that
ree testosterone contributes more to the BNP variability in
omen than estrogens. Consistent with our observations,
estosterone suppressed volume-stimulated release of atrial
atriuretic peptide from isolated perfused rat atria (19). The
roposed primary role of testosterone can still be consistent
ith previous reports of an estrogen effect. Since higher
irculating estrogens will lower free testosterone (by increas-
nfluence of Hormones on the Association Between Body Composit
Table 4 Influence of Hormones on the Association Between Bo
Log-Transformed BN
Beta  SE Betastand
Model 1 (Baseline)
Body mass index 0.016 0.008 0.0
Model 2
Body mass index 0.005 0.008 0.0
Log (sex hormone-binding globulin) 0.403 0.104 0.1
Model 3
Body mass index 0.005 0.008 0.0
Log (free androgen index) 0.320 0.075 0.1
Model 4
Body mass index 0.006 0.008 0.0
Log (calculated free testosterone) 0.329 0.080 0.1
Model 5
Total fat mass‡ 0.000007 0.000005 0.0
Model 6
Total lean mass§ 0.00002 0.000008 0.1
Model 7
Total lean mass§ 0.00001 0.000009 0.0
Log (sex hormone-binding globulin) 0.372 0.103 0.1
Model 8
Total lean mass§ 0.00001 0.000009 0.0
Log (free androgen index) 0.298 0.075 0.1
Model 9
Total lean mass§ 0.00001 0.000009 0.0
Log (calculated free testosterone) 0.306 0.081 0.1
Models adjusted for age, creatinine, left ventricular ejection fraction55%, left ventricular mass,
oefficient compares the relative strength of each variable in the model by standardizing the unit
ean mass.
Abbreviations as in Table 3.ng SHBG), the effect of exogenous estrogen may have been Hediated through lowering free testosterone. Similarly, the
ifferences between pubertal boys and girls might represent
he “BNP-lowering” effects of rising testosterone produc-
ion in boys rather then “BNP-raising” effects associated
ith higher estrogen concentrations at menarche in girls.
en and women differ more by circulating testosterone
oncentrations than by estrogen concentrations. Total tes-
osterone ranges in men are an order of magnitude larger
han those in women, and free testosterone is almost 40
imes greater in men than in women. In contrast, estradiol
oncentrations are usually only 1 to 2 times greater in
omen than in men (20).
The present findings lead to a rephrasing of the question,
rom “why do women have higher natriuretic peptides?” to
why do men have lower natriuretic peptides?” Men may
ave a natriuretic peptide handicap, or impaired natriuretic
eptide response, as has been previously proposed with
egard to obesity (6,21). Viewing gender differences in BNP
n this light, we speculate that modestly higher BNP
oncentrations in young women may contribute to cardio-
rotection before menopause. For example, BNP has estab-
ished antiproliferative and vasodilatory effects and has been
hown to act as a counter-regulatory hormone in the
enin-angiotensin-aldosterone and adrenergic axes (22).
nd Natriuretic Peptides*
mposition and Natriuretic Peptides*
Log-Transformed NT-proBNP
p Value Beta  SE Betastandardized† p Value
0.046 0.016 0.006 0.112 0.008
0.53 0.003 0.006 0.024 0.59
0.0001 0.483 0.077 0.251 0.0001
0.53 0.005 0.006 0.036 0.41
0.0001 0.328 0.056 0.234 0.0001
0.48 0.006 0.006 0.041 0.34
0.0001 0.335 0.060 0.221 0.0001
0.15 0.000007 0.000004 0.085 0.044
0.004 0.00002 0.000006 0.169 0.001
0.095 0.000009 0.000006 0.072 0.17
0.0003 0.465 0.076 0.241 0.0001
0.12 0.000009 0.000006 0.076 0.15
0.0001 0.317 0.056 0.226 0.0001
0.11 0.000010 0.000006 0.082 0.12
0.0002 0.323 0.060 0.213 0.0001
ral estrogen use, post-menopausal, and log (follicle stimulating hormone); †the standardized beta
el replacing body mass index with total fat mass; §models replacing body mass index with totalion a
dy Co
P
ardized†
86
29
62
28
77
32
68
62
53
92
50
84
65
89
57
race, o
s; ‡modigher pre-menopausal natriuretic peptide concentrations
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January 2/9, 2007:109–16 Androgens, Estrogens, and Natriuretic Peptidesay in part mediate the relative protection against LVH in
oung women. The relative decrease in natriuretic peptides
ith age may help to explain the marked increase in LVH
fter menopause observed in healthy women from the
ramingham study (3,23). Although menopause is tradi-
ionally considered a time of falling estrogens, it is also a
ime in which free testosterone concentrations rise signifi-
antly. In a prospective study of women during the meno-
ause transition, the FAI increased with time relative to the
nal menstrual period by as much as 80% during the course
f 6 years (24).
ody composition, natriuretic peptides, and free testos-
erone status. Previous studies have reported an inverse
ssociation between BMI and natriuretic peptides, an ob-
ervation that was thought to result from increased BNP
learance by the natriuretic peptide clearance receptor in
dipose tissue (25). However, we and others have recently
eported similar associations for N-terminal-pro-atrial na-
riuretic peptide and NT-proBNP (6,18), which do not
ind the clearance receptor, suggesting that the association
etween obesity and lower natriuretic peptide concentra-
ions is more likely mediated by reduced natriuretic peptide
roduction and/or release than by enhanced clearance.
oreover, using DEXA measurements of body composi-
ion, we discovered that lean mass rather than fat mass
rimarily accounted for the inverse association between
MI and natriuretic peptides.
We extend these previous findings here with the obser-
ation that measures of free testosterone status modified the
ffect of BMI and lean mass on BNP and NT-proBNP,
uch that BMI and lean mass were no longer significantly
ssociated with BNP or NT-proBNP after adjusting for
easures of free testosterone. These findings suggest that
ree testosterone, which can increase lean mass and may
irectly decrease natriuretic peptide synthesis, may be an
mportant mediator of the association between body com-
osition and natriuretic peptides. These results highlight the
ignificance of lean mass, even in obese subjects, and suggest
hat important confounders or effect-modifiers, including free
estosterone, may contribute to the complex relationship de-
cribed between BMI and cardiovascular disease (26).
HBG and testosterone measurements in women. SHBG
s a transport protein for estrogens, testosterone, and other
ndrogens that has a greater affinity for testosterone than for
stradiol, such that SHBG gives a relative indication of the
atio of free estradiol to free testosterone. In women, SHBG
s present in large excess; the ratio of SHBG:testosterone is
0 to 100:1. When estradiol increases, steady-state SHBG
oncentrations increase and subsequently lower the amount
f unbound or free testosterone. With higher circulating
estosterone, SHBG production is suppressed and even
ore unbound circulating free testosterone is available.
herefore, in women, SHBG has a strong inverse relation-
hip with free testosterone concentrations such that high
HBG correlates with low free testosterone and low SHBG
orrelates with high free testosterone (20).Low concentrations of SHBG have been associated with
ncreased cardiovascular risk in both pre- and post-menopausal
omen (27,28). In the Women’s Health Study, SHBG was
nversely related to C-reactive protein in post-menopausal
omen who developed clinical cardiovascular disease (29). Our
ata associate lower SHBG concentrations with lower concen-
rations of natriuretic peptides. Given the cardioprotective
ffects of natriuretic peptides, including antiproliferative and
asodilatory effects, as well as antagonism of the renin-
ngiotensin-aldosterone and adrenergic axes (22), we speculate
hat lower natriuretic peptide concentrations may explain, in
art, the excess cardiovascular risk associated with low SHBG
oncentrations. Future studies should evaluate whether the
ame relationships among SHBG, free testosterone, and na-
riuretic peptide levels persist in older women as well as in men.
tudy limitations. Blood samples were not timed to the
enstrual cycle, and analyte measurements were not dupli-
ated. We did not perform direct measures of estrogen or
ree estrogen concentrations, nor did we perform measure-
ents of free testosterone using the traditional equilibrium
ialysis method. However, cFT correlates well with free
estosterone measured by equilibrium dialysis (13). Because
hese are cross-sectional data, we were not able to determine
he clinical significance of hormone-related differences in
NP and NT-proBNP.
onclusions. Among a population-based sample of young
omen, measures of free testosterone were independently
nd inversely associated with circulating BNP and NT-
roBNP, whereas various measures of estrogen status were
ot. We found that BMI and lean body mass were no longer
ignificantly associated with BNP or NT-proBNP after
djustment for free testosterone measurements. These data
uggest that gender differences in natriuretic peptides, and
otentially the previously observed inverse relationship of
NP and NT-proBNP with BMI, reflect an inhibitory
ffect of testosterone in men rather than a stimulatory effect
f estradiol in women. Additional investigation is needed to
est this hypothesis in older women, in men, and in subjects
ith normal and overweight BMI. Future studies modeling
atriuretic peptide regulation should include a parameter to
ontrol for the influence of free testosterone.
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